NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
Mark Cherney is the Founder and Executive Chairman of both US Urology Partners and Prologics. This past year Mark transitioned from the CEO role...
Dr. Michael Meighen is a physician who is board certified in Physiatry and Pain Medicine. He is the author of #1 Best Selling Book...
With Sage’s AI Driven Medical Coding, Billing and Dictation, practitioners are eliminating the costly overhead of a medical coder while increasing productivity by 20%....
